Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Kymera Therapeutics director sold $631k in stock as revenue dropped 60.8%.
Kymera Therapeutics director Elena Ridloff sold 7,400 shares worth $631,738 on March 31, following a separate sale by another director.
The biopharmaceutical company reported a steep 60.8% drop in revenue and missed analyst earnings expectations.
Despite insider activity, analysts maintain a "Moderate Buy" rating with a target price of $118.90.
3 Articles
El director de Kymera Therapeutics vendió $631 mil en acciones mientras los ingresos caían un 60.8%.